Table 2.

ORR and best response based on investigator/assessment (primary efficacy analysis set; n = 15)

	n (%)	95% CIa
ORRb: CR + PR	13 (86.7)	59.5–98.3
Best response
CR	4 (26.7)	7.8–55.1
PR	9 (60.0)	32.3–83.7
SD	1 (6.7)	0.2–31.9
PD	1 (6.7)	0.2–31.9
Not evaluable	0 (0.0)	0.0–21.8

CI confidence interval, CR complete response, IWG International Working Group, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease

^aBased on the Clopper–Pearson method

^bBased on investigator assessment per the IWG 2007 criteria